Oruka Therapeutics’ (ORKA) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Oruka Therapeutics (NASDAQ:ORKA) in a research report sent to investors on Monday,Benzinga reports. They currently have a $45.00 price objective on the stock. HC Wainwright also issued estimates for Oruka Therapeutics’ Q4 2024 earnings at ($0.39) EPS, FY2024 earnings at ($2.24) EPS, Q3 2025 earnings at ($0.52) EPS and FY2025 earnings at ($1.98) EPS.

Several other analysts have also recently weighed in on ORKA. Leerink Partners assumed coverage on Oruka Therapeutics in a report on Tuesday, September 17th. They set an “outperform” rating and a $44.00 price target for the company. Leerink Partnrs raised shares of Oruka Therapeutics to a “strong-buy” rating in a research report on Tuesday, September 17th. Wedbush reaffirmed an “outperform” rating and set a $40.00 price target on shares of Oruka Therapeutics in a research report on Tuesday, November 19th. Jefferies Financial Group started coverage on shares of Oruka Therapeutics in a report on Friday, September 13th. They issued a “buy” rating and a $40.00 price objective for the company. Finally, TD Cowen assumed coverage on shares of Oruka Therapeutics in a report on Monday, September 16th. They set a “buy” rating on the stock. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $43.17.

Oruka Therapeutics Price Performance

Shares of ORKA stock opened at $20.26 on Monday. Oruka Therapeutics has a 12-month low of $18.20 and a 12-month high of $53.88. The firm has a market capitalization of $709.08 million, a P/E ratio of -3.24 and a beta of 0.87. The stock’s 50 day moving average is $25.76.

Hedge Funds Weigh In On Oruka Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. The Manufacturers Life Insurance Company bought a new stake in shares of Oruka Therapeutics during the 3rd quarter worth $1,037,000. FMR LLC bought a new position in shares of Oruka Therapeutics in the third quarter worth about $114,763,000. Great Point Partners LLC acquired a new stake in shares of Oruka Therapeutics in the 3rd quarter valued at approximately $12,614,000. Braidwell LP bought a new stake in shares of Oruka Therapeutics during the 3rd quarter valued at approximately $12,640,000. Finally, Janus Henderson Group PLC acquired a new position in Oruka Therapeutics during the 3rd quarter worth approximately $5,840,000. Institutional investors own 56.44% of the company’s stock.

About Oruka Therapeutics

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.